The University of Kansas Cancer Center Senior Leadership team is led by the Director, who is assisted by the Deputy Director, the Chief Operating Officer, and seven Associate Directors. The team meets bi-monthly, to discuss matters pertaining to the four research programs and their scientific progress;the four shared resources and their cost effectiveness, utilization, and quality;ad hoc budget requests from Cancer Center members;space allocation requests;new shared resources or shared equipment requests;and set all Cancer Center policies and procedures. The Senior Leaders also meet regularly in the context of the Cancer Center's Leadership Council (every other month). Program Leader (every other month) and/or Shared Resource meetings (quarterly). Collectively the Senior Leadership has ultimate responsibility for identifying, developing, and implementing intra- and inter-programmatic collaborative research opportunities. Each Senior Leader contributes a special expertise that collectively provides the Director counsel related to the development and growth of the Cancer Center's clinical trial portfolio, shared resources, basic, translational, clinical and population sciences, and research base and funding resources.

Public Health Relevance

KUCC Senior Leadership provides the vision, direction, expertise, guidance, leadership and experience that is critical to the growth, development, and success of The University of Kansas Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-03
Application #
8702106
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$727,872
Indirect Cost
$510,000
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Ledgerwood, Levi G; Kumar, Dhruv; Eterovic, Agda Karina et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7:27185-98
Reed, Gregory A; Schiller, Gary J; Kambhampati, Suman et al. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5:3031-3040
Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89
Parsel, S M; Grandis, J R; Thomas, S M (2016) Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 35:3217-26
(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Mitchell, Julie L; Seng, Amara; Yankee, Thomas M (2016) Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes. Immunology 149:400-412
Hamilton-Reeves, Jill M; Bechtel, Misty D; Hand, Lauren K et al. (2016) Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol 69:389-92
Kurahara, Hiroshi; Bohl, Christopher; Natsugoe, Shoji et al. (2016) Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 139:628-38
Jiang, Yu; Guarino, Peter; Ma, Shuangge et al. (2016) Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application. Trials 17:336
(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401

Showing the most recent 10 out of 93 publications